Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 2

13:27 EST 12th December 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 26–50 of 8,100+

Probably Relevant

Summit Therapeutics plc: Result of AGM

Summit Therapeutics plc ('Summit' or the 'Company')Result of Annual General MeetingOxford, UK, and Cambridge, MA, US, 7 June 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that...


4D Molecular Therapeutics Scores $90 Million in Series B Funding

4D Molecular Therapeutics snagged $90 million in a Series B financing round. The company intends to use the funds to advance its Therapeutic Vector Evolution platform and pipeline of next-generation AAV gene therapeutics.

Spark Therapeutics, Inc.: Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights

PHILADELPHIA, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...


Neon Therapeutics Announces Pricing of Initial Public Offerings

Neon Therapeutics (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. As quoted in the press release: In addition, Neon Therapeutics has granted the underwriters ...

Tusk Therapeutics Ltd: Tusk Therapeutics to be acquired by Roche

Tusk Therapeutics to be acquired by Roche Stevenage, United Kingdom - September 28th 2018: Tusk Therapeutics Ltd ("Tusk") was today acquired by Roche. Tusk has developed an antibody with a novel m...

Abeona Therapeutics Inc.: Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights

Investor Conference Call on Monday, November 12th at 10:00 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biophar...

Click Therapeutics Lands $17M to Advance Prescription Digital Therapeutics Platform

Click Therapeutics, Inc. (“Click”), a provider of Digital Therapeutics solutions as prescription medical treatments, has raised $17 million in funding led by Sanofi Ventures, the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sano...

Shionogi Enters Into A License And Research Collaboration With Hsiri Therapeutics

NewsThe companies have entered into a license agreement regarding a collaborative licensing, research, and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB).

Rubius Therapeutics Looks to Raise $200 Million in IPO for Red-Cell Therapies

Three months after securing $100 million in a crossover financing round, Cambridge, Mass.-based Rubius Therapeutics is looking at a $200 million initial public offering to support its personalized red blood cell therapeutics program.

Spark Therapeutics, Inc.: Spark Therapeutics Recognized for Second-straight Year as One of Philadelphia's "Best Places to Work" by the Philadelphia Business Journal

PHILADELPHIA, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced t...

Spark Therapeutics, Inc.: Spark Therapeutics wurde vom Philadelphia Business Journal zum zweiten Mal in Folge als einer von Philadelphias "besten Arbeitgeber" ausgezeichnet

PHILADELPHIA , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar sind,...

Small-Cap Snapshot: Unum Therapeutics shares rise on news of upcoming investor presentation

Small cap names on the move today are: Unum Therapeutics (NASDAQ:UMRX), Beazer Homes (NYSE:BZH), CymaBay Therapeutics Inc (NASDAQ:CBAY), Madrigal Pharmaceuticals (NASDAQ:MDGL). 

M&As this week: PTC Therapeutics, Cambrex

PTC Therapeutics has signed an agreement to acquire Agilis Biotherapeutics for $945m. Agilis Biotherapeutics’ product pipeline includes four gene therapies programmes...Read More... The post M&As this week: PTC Therapeutics, Cambrex appeared first on Pharmaceutical Technology.

Evox raises £35m for exosome therapeutics

Oxford, UK-based Evox Therapeutics has raised £35 million to help advance its exosome-based therapeutics pipeline.

Jnana, Neurocrine enter discovery pact for small-molecule CNS disorder therapeutics

Jnana Therapeutics Inc. and Neurocrine Biosciences Inc. are allying to discover multiple targets from which to develop small-...

Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante Therapeutics

- Acquisition adds Zavante’s CONTEPO™, potential first-in-class in the United States injectable antibiotic for cUTIs, to Nabriva’s late-stage anti-infective portfolio - - Nabriva on track to file New Drug Applications for lefamulin and CONTEPO in the fourth quarter of 2018 - - Ted Schroeder appointed as Nabriva’s CEO to continue Nabriva’s path to commercialization; Dr. Colin Broom to...

e-therapeutics sees biopharma sector get in tune with its way of thinking

E-therapeutics believes it is now focused on the right activities

Summit Therapeutics plc: Director/PDMR Shareholding

Summit Therapeutics plc ('Summit', the 'Company', or the 'Group')Director / PDMR Share DealingOxford, UK, Cambridge, MA, US, 16 July - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces ...

Time To Buy Emerald Health Therapeutics After It Lost 50 pct In October?

Emerald Health Therapeutics is our favorite cannabis stock. We explained in great detail in our Emerald Health Therapeutics Stock Forecast for 2019 that we have a price target of $38. This is based...

OMEICOS Therapeutics Closes €17m Series C Financing

OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced the closing of a EUR 17 million (approx. USD 19.5 million) Series C financing led by new in...

Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics

SAN DIEGO, July 23, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced the achievement of key milestones as part of its agreement with Cystic Fibrosis Foundation (CF Foundation) Therapeutics, Inc. The completion of these success-driven milestones has triggered an undisclosed payment to Arcturus from the CF Foundation to advance LU...

Rubius Therapeutics to Acquire Manufacturing Facility in Smithfield, Rhode Island to Produce Red Cell Therapeutics

CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today announced that it has signed a purchase and sale agreement for the acquisition of a 135,000-square foot manufacturing facility located in Smithfield, Rhode Island. The company plans to invest up t...

Pain Therapeutics Will Make the Case for an FDA Reversal on Remoxy

Texas-based Pain Therapeutics is urging the FDA to reconsider the Complete Response Letter it issued in August for the company’s opioid-treatment, Remoxy. Representatives from Pain Therapeutics will meet with the FDA on Jan. 31. 2019 to discuss the request, the company announced late Monday.

Evox Therapeutics raises new funds to support drug development

UK-based therapeutics developer Evox Therapeutics has secured $45.4m in a series B financing round to support new drug development. The...Read More... The post Evox Therapeutics raises new funds to support drug development appeared first on Pharmaceutical Technology.

The Current issue of “The view from here” is concerned with Novel Therapeutics.

The topic of this month’s newsletter from Drug Discovery Today is Novel Therapeutics.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks